Low-Fat Breakfasts Could Weaken Effect of a Key Lung Cancer Drug, Alecensa
Medically reviewed by Drugs.com.
By Steven Reinberg HealthDay Reporter
WEDNESDAY, June 14, 2023 -- The lung cancer drug alectinib (Alecensa) is more potent when taken with a fuller breakfast, or lunch, than when taken with a low-fat breakfast, researchers report.
The Dutch team evaluated 20 patients who took one of two daily doses of alectinib with either low-fat yogurt alone, a full continental breakfast, or a lunch of their choosing. Low-fat yogurt resulted in 14% less exposure to the drug than a continental breakfast, and 20% less than lunch, the researchers found.
The report was published June 12 in the JNCCN, Journal of the National Comprehensive Cancer Network.
"This is important information for patients, since we know that higher alectinib concentrations in blood could result in more efficacy of the drug, a longer treatment duration and therefore, hopefully, a better survival," said lead researcher Daan Lanser, from the Erasmus Cancer Institute at Erasmus University Medical Center in the Netherlands.
"Sometimes, we hear that patients are advised to take their twice daily alectinib strictly 12 hours apart, with the result that some patients will take it with just a small snack in the morning or evening. We believe that taking it with a substantial meal containing enough fat is far more important for the absorption and efficacy of the treatment than to wait 12 hours between doses," Lanser said in a journal news release.
"This important study highlights the key role of diet on the efficacy of oral cancer drugs," said Dr. Sandip Patel, a professor of medicine at the University of California, San Diego School of Medicine.
"Medication-diet interactions are just as important as medication-medication interactions for oral cancer treatments," said Patel, who was not involved in this research.
Alectinib is what's known as a small molecule kinase inhibitor. It's used to treat some types of advanced lung cancer. Maintaining therapeutic doses long-term is key to this drug’s activity, Patel explained.
The findings of this study highlight "the need for education and dietary modification for patients taking these drugs long-term," he said in the release.
Sources
- Journal of the National Comprehensive Cancer Network, news release, June 12, 2023
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Science Pinpoints Nutrients Crucial to Brain Health
THURSDAY, May 23, 2024 -- Specific nutrients could play a pivotal role in the healthy aging of your brain, a new study finds. What’s more, those nutrients correlate closely...
Vaping After Quitting Smoking Keeps Lung Cancer Risk High
TUESDAY, May 21, 2024 -- If you've quit smoking and have switched to vaping instead, your odds for lung cancer won't fall as steeply as if you quit nicotine altogether, new...
1 in 4 Parents Say Their Teen Drinks Caffeine Daily
MONDAY, May 20, 2024 -- Many teens are spending their days buzzed on caffeine, with their parents mostly unaware of the potential risks, a new national poll says. A quarter of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
